Brief: Simcere Pharmaceutical Says Clinical Trial Approval For SIM0500 For Injection Issued By NMPA
12/03/2024 12:52
March 12 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* CLINICAL TRIAL APPROVAL FOR SIM0500 FOR INJECTION (A
HUMANIZED
GPRC5D-BCMA-CD3 TRISPECIFIC ANTIBODY) ISSUED BY NMPA
Source text for Eikon: ID:n11096185-1
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660